Osteoprotegerin and kidney disease (Q38206487)

31 August 2017

Osteoprotegerin and kidney disease (English)

1 reference

Maria Dolores Sanchez-niño

31 August 2017

Alvaro C Ucero

4

0 references

object named as

Maria D Sanchez-Niño

3

0 references

Alberto Ortiz

object named as

Alberto Ortiz

6

0 references

author name string

Alejandra Montañez-Barragán

1

1 reference

31 August 2017

Isaias Gómez-Barrera

2

1 reference

31 August 2017

Liliana González-Espinoza

5

1 reference

31 August 2017

23 April 2014

1 reference

31 August 2017

Journal of Nephrology

1 reference

31 August 2017

27

1 reference

31 August 2017

607-617

1 reference

31 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s40620-014-0092-x

31 August 2017

0 references

cites work

Chronic kidney disease: global dimension and perspectives

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Cardiovascular and noncardiovascular mortality among patients starting dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Phosphate: a stealthier killer than previously thought?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

The demise of calcium-based phosphate binders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Klotho, phosphate and inflammation/ageing in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Klotho deficiency causes vascular calcification in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Mechanistic insights into vascular calcification in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Historically significant events in the discovery of RANK/RANKL/OPG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Prevention and treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Signalling pathways of the TNF superfamily: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Tumor necrosis factor receptor superfamily members and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

A family of ligands for the TNF receptor superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

OPG/RANK/RANKL signaling system and its significance in nephrology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

RANK, RANKL and osteoprotegerin in bone biology and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Biology of RANK, RANKL, and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Functions of RANKL/RANK/OPG in bone modeling and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Clinical applications of RANK-ligand inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

The death ligand TRAIL in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

TNF superfamily: a growing saga of kidney injury modulators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

21 January 2018

Trail and kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Mechanistic study of the proangiogenic effect of osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Bilateral giant cavernous carotid artery aneurysms in a child with juvenile Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Impaired renal function is associated with mortality and morbidity after endovascular abdominal aortic aneurysm repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Impact of chronic kidney disease on outcomes after abdominal aortic aneurysm repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Letter by Secchiero and Zauli regarding article, "Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

TRAIL and osteoprotegerin: a role in endothelial physiopathology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

A case-control study of calciphylaxis in Japanese end-stage renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Clinical development of anti-RANKL therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Serum osteoprotegerin as a screening tool for coronary artery calcification score in diabetic pre-dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Bone biomarkers help grading severity of coronary calcifications in non dialysis chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Normal and pathologic concentrations of uremic toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Serum osteoprotegerin and renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

The strange relationship between diabetes and abdominal aortic aneurysm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Calcification of coronary arteries and abdominal aorta in relation to traditional and novel risk factors of atherosclerosis in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Evolution of coronary artery calcifications following kidney transplantation: relationship with osteoprotegerin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Calcium and osteoprotegerin levels predict the progression of the abdominal aortic calcifications after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin inhibits calcification of vascular smooth muscle cell via down regulation of the Notch1-RBP-Jκ/Msx2 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin in exosome-like vesicles from human cultured tubular cells and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Crystal structure of human RANKL complexed with its decoy receptor osteoprotegerin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40620-014-0092-X

21 January 2018

Vascular calcification

1 reference

12 December 2020

Osteoprotegerin as a marker of cardiovascular risk in patients on peritoneal dialysis

1 reference

12 December 2020

Serum receptor activator of nuclear factor-κ B ligand, osteoprotegrin, and intact parathyroid hormone in hemodialysis and renal transplant patients

1 reference

12 December 2020

The nerve growth factor/tumor necrosis factor receptor family.

1 reference

12 December 2020

Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice

1 reference

12 December 2020

FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart

1 reference

12 December 2020

Establishment of OPG Transgenic Mice and the Effect of OPG on Bone Microarchitecture

1 reference

12 December 2020

Role of OPG/RANKL/RANK axis on the vasculature

1 reference

12 December 2020

Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes

1 reference

12 December 2020

Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?

1 reference

12 December 2020

Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease

1 reference

12 December 2020

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome

1 reference

12 December 2020

Osteoprotegerin levels before and after renal transplantation.

1 reference

12 December 2020

23rd Congress of the European Society of Cardiovascular Surgery

1 reference

12 December 2020

Osteoprotegerin induces cytoskeletal reorganization and activates FAK, Src, and ERK signaling in endothelial cells.

1 reference

12 December 2020

Aortic calcification in a patient with hutchinson-gilford progeria syndrome

1 reference

12 December 2020

Bilateral cavernous internal carotid aneurysms in a child with juvenile paget disease and osteoprotegerin deficiency

1 reference

12 December 2020

Types of neurons in nucleus olivaris inferior of the European bison

1 reference

12 December 2020

Elevated osteoprotegerin predicts declining renal function in elderly women: a 10-year prospective cohort study

1 reference

12 December 2020

Rank/Rankl/opg: literature review

1 reference

12 December 2020

Magnesium - its role in CKD.

1 reference

12 December 2020

KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

1 reference

12 December 2020

Osteoprotegerin and fractures in men and women with chronic kidney disease

1 reference

12 December 2020

Early Posttransplant Serum Osteoprotegerin Levels Predict Long-Term (8-Year) Patient Survival and Cardiovascular Death in Renal Transplant Patients

1 reference

12 December 2020

Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder

1 reference

12 December 2020

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

1 reference

12 December 2020

10.1007/S40620-014-0092-X

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

0 references

1 reference